<?xml version='1.0' encoding='utf-8'?>
<document id="31284561"><sentence text="Evaluating the Anti-cancer Efficacy of a Synthetic Curcumin Analog on Human Melanoma Cells and Its Interaction with Standard Chemotherapeutics."><entity charOffset="51-59" id="DDI-PubMed.31284561.s1.e0" text="Curcumin" /></sentence><sentence text="Melanoma is the leading cause of skin-cancer related deaths in North America" /><sentence text=" Metastatic melanoma is difficult to treat and chemotherapies have limited success" /><sentence text=" Furthermore, chemotherapies lead to toxic side effects due to nonselective targeting of normal cells" /><sentence text=" Curcumin is a natural product of Curcuma longa (turmeric) and has been shown to possess anti-cancer activity"><entity charOffset="1-9" id="DDI-PubMed.31284561.s5.e0" text="Curcumin" /></sentence><sentence text=" However, due to its poor bioavailability and stability, natural curcumin is not an effective cancer treatment"><entity charOffset="65-73" id="DDI-PubMed.31284561.s6.e0" text="curcumin" /></sentence><sentence text=" We tested synthetic analogs of curcumin that are more stable"><entity charOffset="32-40" id="DDI-PubMed.31284561.s7.e0" text="curcumin" /></sentence><sentence text=" One of these derivatives, Compound A, has shown significant anti-cancer efficacy in colon, leukemia, and triple-negative inflammatory breast cancer cells" /><sentence text=" However, the effects of Compound A against melanoma cells have not been studied before" /><sentence text=" In this study, for the first time, we demonstrated the efficacy of Compound A for the selective induction of apoptosis in melanoma cells and its interaction with tamoxifen, taxol, and cisplatin"><entity charOffset="163-172" id="DDI-PubMed.31284561.s10.e0" text="tamoxifen" /><entity charOffset="174-179" id="DDI-PubMed.31284561.s10.e1" text="taxol" /><entity charOffset="185-194" id="DDI-PubMed.31284561.s10.e2" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.31284561.s10.e0" e2="DDI-PubMed.31284561.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31284561.s10.e0" e2="DDI-PubMed.31284561.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31284561.s10.e0" e2="DDI-PubMed.31284561.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31284561.s10.e1" e2="DDI-PubMed.31284561.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31284561.s10.e1" e2="DDI-PubMed.31284561.s10.e2" /></sentence><sentence text=" We found that Compound A induced apoptosis selectively in human melanoma cells by increasing oxidative stress" /><sentence text=" The anti-cancer activity of Compound A was enhanced when combined with tamoxifen and the combination treatment did not result in significant toxicity to noncancerous cells"><entity charOffset="72-81" id="DDI-PubMed.31284561.s12.e0" text="tamoxifen" /></sentence><sentence text=" Additionally, Compound A did not interact negatively with the anti-cancer activity of taxol and cisplatin"><entity charOffset="87-92" id="DDI-PubMed.31284561.s13.e0" text="taxol" /><entity charOffset="97-106" id="DDI-PubMed.31284561.s13.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.31284561.s13.e0" e2="DDI-PubMed.31284561.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31284561.s13.e0" e2="DDI-PubMed.31284561.s13.e1" /></sentence><sentence text=" These results indicate that Compound A could be developed as a selective and effective melanoma treatment either alone or in combination with other non-toxic agents like tamoxifen"><entity charOffset="171-180" id="DDI-PubMed.31284561.s14.e0" text="tamoxifen" /></sentence><sentence text="" /></document>